A Phase 2B double-blind, randomized, placebo-controlled, multisite dose-ranging study to assess the efficacy, safety, pharmacokinetics and the optimal dose of bumetanide in children and adolescents with autism spectrum disorder.
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2017
Price : $35 *
At a glance
- Drugs Bumetanide (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- Sponsors Neurochlore
- 22 Mar 2017 New trial record
- 14 Mar 2017 Results published in the Translational Psychiatry.